CorMedix Inc
CRMD
Detailliertes Diagramm anzeigen
14.350USD
+0.210+1.49%
Handelsschluss 08/28, 16:00（ET）Kurse um 15 Minuten verzögert
1.07BMarktkapitalisierung
62.33KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+1.49%
5 Tage
+5.83%
1 Monat
+19.78%
6 Monate
+38.51%
Seit Jahresbeginn
+77.16%
1 Jahr
+138.37%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung
Währung: USD Aktualisiert：2025-08-27Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund.Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch.In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet.Trotz einer sehr schwachen Marktentwicklung zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren.Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
7
Analysten
Kaufen
Aktuelles Rating
19.833
Kursziel
+40.26%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=66363.08%)
performance_growth_period
performance_growth_period_desc%!(EXTRA string=43.47M)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=17.67)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=26.40M, string=22.55%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=4.31M)
activity_increase
activity_increase_desc%!(EXTRA string=1.57)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
BörsenkürzelCRMD
UnternehmenCorMedix Inc
CEOMr. Joseph Todisco
Websitehttps://cormedix.com/
Verwandte Finanzinstrumente
-0.30%
-0.76%
-0.07%
+0.08%
-0.33%
-1.02%
-0.58%
-0.82%
-1.87%
-1.19%
-0.34%
+0.76%
-1.57%
-0.21%
-0.36%
-1.18%
+0.09%
-0.37%
-1.25%
-0.41%
